David G. Hicks

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• 984 SOX17 as a Reliable Diagnostic Marker in Metastatic Tubo-Ovarian and Endometrial Non-Mucinous Carcinomas: A Validation Study of Paired Primary and Secondarily-Involved Non-Gynecologic Tumor Sites

  Laboratory Investigation · 2026-03-01

• Postradiation angiosarcoma of the breast: a 25-year single-institution analysis of clinicopathological characteristics and immunohistochemical biomarker study

  Biotechnic & Histochemistry · 2026-02-16

• Abstract P5-08-09: Validation of the Updated Breast Graded Prognostic Assessment (Breast GPA) for Stereotactic Radiosurgery (SRS) Treated Patients

  Clinical Cancer Research · 2025-06-13

• Abstract P5-12-16: Impact of Metastatic Sites Including Brain and Liver in Overall Survival Among Patients With Breast Cancer

  Clinical Cancer Research · 2025-06-13

• Abstract P5-06-10: Clinical and Transcriptomic Study of Matched Primary Breast Cancer and Brain Metastasis

  Clinical Cancer Research · 2025-06-13

• Rapid Malignant Transformation of a Biopsy Proven Sporadic Soft Tissue Schwannoma to Spindle Cell MPNST With <i>TP53</i> Mutation as an Early Event

  International Journal of Surgical Pathology · 2025-05-23

• Systemic Disease Impacts CNS Disease Control After SRS in Patients with Breast Cancer Brain Metastases (P1-6.006)

  Neurology · 2025-04-07

• 1109 Clinical Effect of Pembrolizumab in Uterine Serous Carcinoma May be Affected by HER2 Status and Related Genetic Landscape

  Laboratory Investigation · 2025-03-01

• 1108 HER2-Targeted Treatment in Uterine Serous Carcinoma: Real-World Trastuzumab Use and HER2-Low Expression

  Laboratory Investigation · 2025-03-01

• 982 Impact of HER2 Scoring Criteria on Potential Eligibility for T-DXd Therapy in Uterine Serous Carcinoma

  Laboratory Investigation · 2025-03-01

• Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study)

  npj Breast Cancer · 2024-08-02 · 1 citations

• BMRK-06 BRAIN METASTASIS FREE SURVIVAL OF HER2 LOW AND HER2 ZERO TRIPLE NEGATIVE METASTATIC BREAST CANCER: A WILMOT CANCER INSTITUTE EXPERIENCE (THE HERZELO-TNBC STUDY)

  Neuro-Oncology Advances · 2024-08-01

• Best practices for achieving consensus in <scp>HER2</scp>‐low expression in breast cancer: current perspectives from practising pathologists

  Histopathology · 2024-07-08 · 11 citations